Dozens of New Risperdal Lawsuits Filed in Pennsylvania Litigation, Bernstein Liebhard LLP Reports

Share Article

The Firm is representing numerous individuals in Risperdal lawsuits that are currently pending in the Pennsylvania proceeding, all of which allege the antipsychotic drug may cause men and boys to develop gynecomastia.

Free Case Review
Our Firm is representing numerous individuals who have filed Risperdal gynecomastia cases in this proceeding, and we continue to receive inquiries from others who claim to have experienced similar complications due to this antipsychotic medication.

Risperdal lawsuits (http://www.risperdallawsuit2014.com/) filed on behalf of individuals who allegedly suffered gynecomastia (male breast growth) and other complications allegedly related to its use continue to mount in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to the Court’s Master Case List, 1,248 claims are now pending in the proceeding. That represents an increase of 45 filings since January 4th, when 1,203 cases were reported. (In Re: Risperdal Litigation, Case Number 100300296).

“Our Firm is representing numerous individuals who have filed Risperdal gynecomastia cases in this proceeding, and we continue to receive inquiries from others who claim to have experienced similar complications due to this antipsychotic medication,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Risperdal. The Firm continues to evaluate potential Risperdal lawsuits on behalf of men and young boys who allegedly experienced excessive breast growth because of the medication.

Risperdal Litigation
Risperdal is an atypical antipsychotic medication approved by the U.S. Food and Drug Administration (FDA) to treat schizophrenia and bipolar disorder in adults and adolescents ages 10-to-17, as well as symptoms associated with irritability in children between 5-and-16 years old with autism. According to recent research, the medication is often prescribed off-label for children with ADHD, even though it has not been specifically approved for such purposes by the FDA.*

According to court documents, all of the Risperdal lawsuits pending in Pennsylvania allege that the drug’s manufacturers, Johnson & Johnson and Janssen Pharmaceuticals, failed to provide patients with adequate warnings about its risks. The lawsuits also claim that the medication was improperly marketed by the defendants for off-label uses, including a number of pediatric indications prior to their 2006 approval by the FDA. Specifically, the Risperdal gynecomastia cases pending in the proceeding claim that Johnson & Johnson and Janssen did not provide adequate warnings regarding the potential for the drug to overstimulate the body’s production of prolactin, a hormone that plays a role in female breast development and lactation. Excessive levels of prolactin in men and boys can also result in excessive breast growth, painful and swollen breasts, and nipple discharge, according to the lawsuits.

Risperdal lawsuit plaintiffs are not the only parties to raise questions about the defendant’s handling of Risperdal. In November 2013, Johnson & Johnson and Janssen agreed to pay $2.2 billion to settle criminal and civil charges levied by the U.S. Department of Justice regarding the marketing of several medications, including Risperdal. While the drug makers did plead guilty to promoting Risperdal for off-label use in elderly dementia patients, court records indicate that they did not admit wrongdoing in resolving any of the other allegations, including claims that they had marketed Risperdal for off-label use in children. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Men and boys who developed gynecomastia allegedly due to their use of Risperdal may be entitled to compensation for their injury-related damages. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website